Related Experiment Video
Updated: Apr 13, 2026
10:04
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
2.0K
Transforming tumor cells into professional antigen-presenting cells using poly(β-amino ester) nanoparticles to
Amanda Katharina Binder1,2,3,4, Franziska Bremm1,2,3,4, Niklas Feuchter1,2,3,4
1Department of Dermatology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Uniklinikum Erlangen, Erlangen, Germany. jan.doerrie@uk-erlangen.de.
Nanoscale Horizons
|April 12, 2026
Summary
Researchers engineered tumor cells to express CD80, enhancing T-cell activation against cancer. This novel approach uses messenger RNA (mRNA) delivered by nanoparticles, showing promise for effective cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Effective T-cell activation requires both antigen recognition and co-stimulation.
- Tumor cells often lack co-stimulatory molecules, hindering anti-tumor immune responses.
- Current strategies aim to overcome this limitation by enhancing tumor cell antigen presentation.
Purpose of the Study:
- To convert tumor cells into antigen-presenting cell (APC)-like cells by expressing CD80.
- To evaluate the efficacy of messenger RNA (mRNA)-loaded poly-(beta aminoester) (pBAE) nanoparticles for delivering CD80 mRNA to tumor cells.
- To assess the potential of this approach for cancer immunotherapy.
Main Methods:
- Tumor cell lines (melanoma, lung cancer, leukemia, etc.) were electroporated or transfected with CD80-encoding mRNA.
- Poly-(beta aminoester) (pBAE) nanoparticles were used to encapsulate and deliver CD80 mRNA.
- T-cell activation, proliferation, and tumor cell killing were assessed in vitro and in vivo models.
Main Results:
- CD80 expression significantly enhanced tumor cell ability to stimulate tumor-antigen-specific T cells.
- pBAE nanoparticles efficiently delivered CD80 mRNA to various cancer cell lines, achieving high expression levels.
- CD80-expressing tumor cells primed and expanded tumor-specific T cells, which effectively killed non-transfected tumor cells and reduced checkpoint receptor expression.
Conclusions:
- Conversion of tumor cells into professional APC-like cells via CD80 mRNA delivery is feasible.
- This strategy results in potent anti-tumor CD8+ T-cell responses and holds promise for cancer treatment.
- mRNA-loaded pBAE nanoparticles provide a viable platform for in vivo application in various cancers.
